Esperion Therapeutics (ESPR) Common Equity (2018 - 2025)
Historic Common Equity for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$451.4 million.
- Esperion Therapeutics' Common Equity fell 2192.06% to -$451.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$451.4 million, marking a year-over-year decrease of 2192.06%. This contributed to the annual value of -$388.7 million for FY2024, which is 1456.55% up from last year.
- According to the latest figures from Q3 2025, Esperion Therapeutics' Common Equity is -$451.4 million, which was down 2192.06% from -$433.5 million recorded in Q2 2025.
- Over the past 5 years, Esperion Therapeutics' Common Equity peaked at -$196.9 million during Q4 2021, and registered a low of -$455.0 million during Q4 2023.
- Over the past 5 years, Esperion Therapeutics' median Common Equity value was -$344.2 million (recorded in 2024), while the average stood at -$345.6 million.
- In the last 5 years, Esperion Therapeutics' Common Equity tumbled by 414804.69% in 2021 and then soared by 1891.48% in 2022.
- Esperion Therapeutics' Common Equity (Quarter) stood at -$196.9 million in 2021, then crashed by 64.4% to -$323.8 million in 2022, then crashed by 40.53% to -$455.0 million in 2023, then increased by 14.57% to -$388.7 million in 2024, then fell by 16.11% to -$451.4 million in 2025.
- Its Common Equity stands at -$451.4 million for Q3 2025, versus -$433.5 million for Q2 2025 and -$426.2 million for Q1 2025.